Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.
Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, Yamane T, Seki N, Nakagawa M.
Biochem Biophys Res Commun. 2012 Jan 6;417(1):588-93. Epub 2011 Dec 9.
Related citations
Robot-assisted nerve-sparing radical cystectomy with bilateral extended pelvic lymph node dissection (PLND) and intracorporeal urinary diversion for bladder cancer: initial experience in 27 cases.
Canda AE, Atmaca AF, Altinova S, Akbulut Z, Balbay MD.
BJU Int. 2011 Dec 16. doi: 10.1111/j.1464-410X.2011.10794.x. [Epub ahead of print]
Probiotics, dendritic cells and bladder cancer.
Feyisetan O, Tracey C, Hellawell GO.
BJU Int. 2012 Jun;109(11):1594-7. doi: 10.1111/j.1464-410X.2011.10749.x. Epub 2011 Dec 16.
The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression.
Fredericks WJ, McGarvey T, Wang H, Lal P, Puthiyaveettil R, Tomaszewski J, Sepulveda J, Labelle E, Weiss JS, Nickerson ML, Kruth HS, Brandt W, Wessjohann LA, Malkowicz SB.
DNA Cell Biol. 2011 Nov;30(11):851-64. Epub 2011 Jul 8.
Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer.
Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; the Nordic Urothelial Cancer Group.
Eur Urol. 2012 Jun;61(6):1229-1238. Epub 2011 Dec 13.
Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer.
Yutkin V, Chin J.
Expert Opin Investig Drugs. 2012 Feb;21(2):251-60. Epub 2011 Dec 21. Review.
Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines.
Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T, Tachiwada T, Seki N, Nakagawa M.
Int J Oncol. 2012 Apr;40(4):951-9. doi: 10.3892/ijo.2011.1294. Epub 2011 Dec 13.
p53 status in locally advanced bladder cancer.
Dizdar O, Demirci U.
J Clin Oncol. 2012 Jan 20;30(3):339; author reply 339-40. Epub 2011 Dec 19. No abstract available.
Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder.
Törzsök P, Riesz P, Kenessey I, Székely E, Somorácz A, Nyirády P, Romics I, Schaff Z, Lotz G, Kiss A.
J Histochem Cytochem. 2011 Nov;59(11):1022-30. doi: 10.1369/0022155411424606.
Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility.
Salinas-Sánchez AS, Donate-Moreno MJ, López-Garrido MP, Giménez-Bachs JM, Escribano J.
J Urol. 2012 Feb;187(2):700-6. Epub 2011 Dec 16.
Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.
Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, McGovern F, Shipley WU.
J Urol. 2012 Feb;187(2):463-8. Epub 2011 Dec 15.
Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
Herr HW.
J Urol. 2012 Feb;187(2):435-7. Epub 2011 Dec 15.
Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
Reis LO, Ferreira U, Billis A, Cagnon VH, Fávaro WJ.
J Urol. 2012 Feb;187(2):438-45. Epub 2011 Dec 15.
Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes.
Meijer RP, Nunnink CJ, Wassenaar AE, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W, Horenblas S.
J Urol. 2012 Feb;187(2):446-50. Epub 2011 Dec 15. Erratum in: J Urol. 2012 Apr;187(4):1513. Meijer, R P P [corrected to Meijer, R P].
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.
J Urol. 2012 Feb;187(2):457-62. Epub 2011 Dec 15.
Using gene polymorphisms to assess bladder cancer risk: progress and challenges.
Kiltie AE.
J Urol. 2012 Feb;187(2):379-80. Epub 2011 Dec 15. No abstract available.
Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort.
Jaiswal PK, Goel A, Mandhani A, Mittal RD.
Mol Biol Rep. 2012 May;39(5):5615-21. Epub 2011 Dec 23.
Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer.
Sun XF, Sun ZY, Pan B, Li L, Shen W.
Mol Biol Rep. 2012 May;39(5):5631-6. Epub 2011 Dec 22.
Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer.
Wu D, Tao J, Xu B, Li P, Lu Q, Zhang W.
Mol Med Report. 2012 Mar;5(3):695-9. doi: 10.3892/mmr.2011.711. Epub 2011 Dec 14.
Bladder cancer in 2011: the dawn of personalized medicine.
Flaig TW, Theodorescu D.
Nat Rev Urol. 2011 Dec 20;9(2):65-6. doi: 10.1038/nrurol.2011.220. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on